Defunct Company
Total Trials
42
As Lead Sponsor
34
As Collaborator
8
Total Enrollment
5,268
NCT00005995
AE-941 in Treating Patients With Metastatic Kidney Cancer
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2000
Completion: Not specified
NCT00022282
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase 2
Start: Apr 30, 2001
NCT00398697
Phase I Perifosine and Gemcitabine Study
Phase: Phase 1
Start: Aug 31, 2004
Completion: Jan 31, 2006
NCT00399789
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Phase: Phase 1/2
Start: Sep 30, 2004
Completion: Dec 31, 2011
NCT00399087
Phase I Trial of Docetaxel With Perifosine
Start: Nov 30, 2004
Completion: Jan 31, 2011
NCT00399126
Phase I Trial of Paclitaxel With Perifosine
Completion: Oct 31, 2011
NCT00389077
Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas
Start: Jan 31, 2005
Completion: Sep 30, 2011
NCT00378495
Miltefosine for Brazilian Visceral Leishmaniasis
Role: Collaborator
Start: Apr 30, 2005
Completion: Oct 31, 2007
NCT00398879
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
Start: Aug 31, 2005
NCT00375791
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
Start: Dec 31, 2005
NCT00628121
Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer
Phase: N/A
Start: Apr 30, 2006
Completion: Feb 28, 2007
NCT00401011
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Start: Aug 31, 2006
Completion: Jul 31, 2011
NCT00455559
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
NCT00391560
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
Start: Oct 31, 2006
NCT00398710
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
NCT00398814
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
NCT00399152
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
Completion: Oct 31, 2009
NCT00401388
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Start: Nov 30, 2006
NCT00415064
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
Start: Dec 31, 2006
Completion: Jul 31, 2012
NCT00448721
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
Start: Mar 31, 2007
NCT00449150
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Completion: Dec 31, 2009
NCT00448747
Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
Start: Jun 30, 2007
NCT00498966
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Start: Jul 31, 2007
NCT00600548
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
Completion: Jul 31, 2009
NCT00569257
Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
Start: Dec 31, 2007
NCT00663858
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Start: Mar 31, 2008
Completion: Jan 31, 2010
NCT00670306
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Completion: Aug 31, 2009
NCT00847366
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
Start: May 31, 2008
Completion: Dec 31, 2012
NCT00776867
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Start: Oct 31, 2008
Completion: Jul 31, 2017
NCT01048580
Study of Perifosine + Capecitabine for Colon Cancer Patients
Start: Oct 31, 2009
NCT01002248
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Start: Dec 31, 2009
Completion: Mar 31, 2013
NCT01049841
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Start: Jan 31, 2010
Completion: Mar 31, 2017
NCT01097018
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Start: Apr 30, 2010
Completion: Apr 30, 2012
NCT01240629
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Start: Nov 2, 2010
Completion: Feb 2, 2017
NCT01234519
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Start: Nov 30, 2010
Completion: Nov 30, 2014
NCT01224730
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
Start: Jan 24, 2012
Completion: Nov 4, 2013
NCT01614990
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Start: May 31, 2012
Completion: Dec 31, 2021
NCT01698281
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Start: Dec 31, 2012
Completion: Oct 31, 2014
NCT01767155
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Start: Apr 30, 2013
Completion: Jan 30, 2017
NCT02238496
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Start: Dec 8, 2014
Completion: Feb 14, 2021
NCT02558829
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Start: Dec 3, 2015
Completion: Nov 29, 2016
NCT04786873
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
Start: Nov 16, 2021
Completion: Jun 13, 2024